Product Description
Belotecan (Camtobell, Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/17823384/)
Mechanisms of Action: TOP1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Korea
Approved Indications: None
Known Adverse Events: None
Company: Chong Kun Dang
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Small Cell Lung Cancer
Phase 2: Small Cell Lung Cancer|Uterine Cancer|Cervical Cancer|Non-Small-Cell Lung Cancer|Ovarian Cancer
Phase 1: Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT00177281 | P1 |
Completed |
Oncology Unspecified |
2006-05-01 |
|
| NCCCTS-06-214 | P2 |
Completed |
Cervical Cancer|Uterine Cancer |
2009-08-01 |
|
| CDR0000614308 | P2 |
Completed |
Small Cell Lung Cancer |
2010-05-01 |
|
| COMBAT | P3 |
Completed |
Small Cell Lung Cancer |
2013-02-01 |
|
| 11NSCLC08K | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2010-02-01 |
|
| 11SCLC09I | P2 |
Completed |
Small Cell Lung Cancer |
2017-12-01 |
|
| 11AOC09J | P2 |
Completed |
Ovarian Cancer |
2014-06-01 |
|
| 2011-GIRBA-2550 | P2 |
Unknown status |
Small Cell Lung Cancer |
2018-07-01 |